FibroBiologics, Inc. (FBLG) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US31573L2043

Price
0.97 USD
Market cap
6.44 m USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
-302.89 %
Return on assets (ROA)
-193.85 %

FibroBiologics, Inc. financials

Fiscal year20252026
Revenue–0.00 USD
Gross profit–-832,000.00 USD
Operating income-16.65 m USD-16.65 m USD
EBIT-18.69 m USD–
Net income-18.65 m USD-18.65 m USD
Diluted EPS – continuing operations-0.42 USD–

Full history since 2021, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About FibroBiologics, Inc.

FibroBiologics, Inc., a clinical-stage biotechnology company, engages in the development and commercialization of fibroblast-based therapies for patients suffering from chronic diseases. The company's product pipeline includes CYWC628 which has completed pre-clinical trial for the treatment of wound healing; CYMS101 which has completed Phase 1 trial for the treatment of multiple sclerosis; CybroCell for the treatment of degenerative disc disease; and CYPS317 for the treatment of psoriasis. It also develops early-stage research products, including CYTER915 to treat the human longevity; and TCB190 for the treatment of certain cancers. FibroBiologics, Inc. was incorporated in 2021 and is headquartered in Houston, Texas.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 12.11.2026. Details in the risk notice.